Insider Trading March 19, 2026

Vita Coco CFO Executes Two 10b5-1 Sales Totaling $235,920

Corey Baker sold 4,000 shares across March 17-18, 2026; firm's analyst coverage and board additions also updated

By Maya Rios COCO
Vita Coco CFO Executes Two 10b5-1 Sales Totaling $235,920
COCO

Corey Baker, chief financial officer of Vita Coco Company, Inc. (NASDAQ: COCO), disposed of 4,000 shares in two Rule 10b5-1 transactions on March 17 and 18, 2026, receiving a combined $235,920. The filings show remaining direct holdings and disclose outstanding non-qualified stock options. The company also recorded fresh analyst price-target lifts and a board appointment in recent updates.

Key Points

  • Corey Baker sold 4,000 shares of Vita Coco stock in two transactions on March 17-18, 2026, totaling $235,920.
  • Sales followed a Rule 10b5-1 trading plan; Form 4 was signed March 19, 2026, by attorney-in-fact Alison Klein.
  • Analysts updated targets and forecasts - Evercore ISI raised its price target to $70 (Outperform) citing a 51.1% scanner-data sales surge; Morgan Stanley lifted its target to $57 and increased fiscal 2026 and 2027 adjusted EBITDA estimates by 11% and 12%, respectively. Vita Coco added retail veteran Shelley Broader to its board.

Corey Baker, chief financial officer at Vita Coco Company, Inc. (NASDAQ: COCO), sold a total of 4,000 shares of the company's common stock in two separate transactions carried out on March 17 and March 18, 2026. According to the company Form 4 filing, the aggregate proceeds from the sales amounted to $235,920, with execution prices ranging between $58.04 and $59.92 per share.

On March 17, Baker sold 2,000 shares at $59.92 per share. After that trade, the filing shows Baker held 29,951 shares of common stock directly. The following day, March 18, he sold another 2,000 shares at $58.04 per share and, subsequent to that transaction, reported direct ownership of 27,951 shares.

The two sales were completed under a Rule 10b5-1 trading plan, the filing states. The Form 4 was signed on March 19, 2026, by Alison Klein, who acted as attorney-in-fact for Baker.

The filing also discloses that Baker holds several non-qualified stock options to acquire additional shares of Vita Coco. The option exercise prices listed in the filing are $16.91, $24.35, $26.18, $27.59 and $33.36. Footnotes in the filing indicate that those options vest over time.


Recent analyst moves and corporate appointment

The company has seen additional activity on the institutional-coverage and corporate-governance fronts. Evercore ISI raised its price target for Vita Coco to $70 while maintaining an Outperform rating. Evercore ISI attributed its target change in part to scanner data showing a 51.1% sales surge in early March, a gain the firm linked to promotional timing and favorable price and mix adjustments.

Morgan Stanley also revised its outlook, lifting its price target to $57. The firm updated its fiscal 2026 and 2027 adjusted EBITDA estimates upward by 11% and 12%, respectively, while retaining an Equalweight rating. Morgan Stanley's new price target is based on a higher enterprise-value-to-EBITDA ratio applied to 2027 estimates.

On the governance side, Vita Coco appointed Shelley Broader to its Board of Directors. Broader brings more than 25 years of retail leadership experience, including roles at Chico's FAS, Inc., Walmart EMEA, Walmart Canada and Sweetbay Supermarkets.


Context and limitations

The Form 4 provides precise transactional details and disclosures about outstanding option grants and the signature date for the filing. It does not prescribe motives for the sales beyond noting that the transactions were carried out pursuant to a Rule 10b5-1 plan. Other developments reported by sell-side analysts and the company are included in the filing and related press communications cited in the filings.

Risks

  • The Form 4 records the insider sales but the filing does not state the seller's motive, leaving investor interpretation of the transactions indeterminate.
  • Outstanding non-qualified stock options at exercise prices of $16.91, $24.35, $26.18, $27.59 and $33.36 vest over time, indicating potential future share issuance if options are exercised.
  • Recent scanner-data sales growth cited by Evercore ISI was attributed to promotional timing and price/mix adjustments, suggesting near-term results can be sensitive to promotional schedules and pricing decisions.

More from Insider Trading

Fairholme Funds Disposes $1.52M in St. Joe Shares; Stake Remains Substantial Mar 19, 2026 Aldeyra CFO Purchases $7,100 in Stock as Company Faces FDA Setback and Executive Departure Mar 19, 2026 Ur‑Energy Finance Executive Adds $149,981 to Stake as Shares Slip Mar 19, 2026 Heritage Insurance CFO-level Sale: Sharon Binnun Disposes of $223,750 in HRTG Stock Mar 19, 2026 Guardant Health Director Sells $30,655 in Shares as Company Posts Q4 2025 Results Mar 19, 2026